Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director of Pulmonology, Allergy, and Rheumatology, to Board of Directors

BOSTON, May 13, 2019 -- (Healthcare Sales &Marketing Network) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF)... Biopharmaceuticals, Personnel Proteostasis Therapeutics, transmembrane conductance regulator, cystic fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

CONCLUSION: Metronidazole, tinidazole, and nitazoxanide are the drugs of choice. Resistance to common antigiardial drugs has increased in recent years. As such, the search for new molecular targets for antigiardial drugs is urgently needed. In general, treatment of asymptomatic carriers is not recommended. Purification of water supply is an important preventive measure. PMID: 31210116 [PubMed - as supplied by publisher]
Source: Recent Patents on Inflammation and Allergy Drug Discovery - Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research
Pediatric Allergy, Immunology, and Pulmonology,Volume 32, Issue 2, Page 45-51, June 2019.
Source: Pediatric, Allergy, Immunology, and Pulmonology - Category: Respiratory Medicine Authors: Source Type: research
What strategies can clinicians use to encourage medication adherence in their cystic fibrosis patients?BMC Pulmonary Medicine
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pulmonary Medicine Journal Article Source Type: news
ConclusionSex, CF ‐related diabetes, sinonasal infection status, allergic rhinitis, and nasal steroid use may all modulate severity of CF‐CRS in adults. Sinusitis exacerbation may be a precursor to pulmonary exacerbation.
Source: International Forum of Allergy and Rhinology - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Posters Sessions Source Type: research
Publication date: May–June 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 5Author(s): Richard H. Stanford, Carlyne Averell, Emily D. Parker, Cori Blauer-Peterson, Tyler K. Reinsch, Ami R. BuikemaBackgroundAlthough efficacy and safety of fluticasone furoate/vilanterol (FF/VI) and budesonide/formoterol (BUD/F) have been demonstrated in clinical studies, real-world comparisons of utilization have not been performed.ObjectiveTo compare similar patients with asthma initiating FF/VI or BUD/F on measures of adherence, persistence, and the asthma medication ratio (AMR).MethodsThis wa...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Mycobacterium abscessus is a rapidly-growing, virulent, non-tuberculous mycobacterium that causes progressive inflammatory lung damage and significant decline in lung functionin patients with cystic fibrosis. M. abscessus complex pulmonary infections are notoriously difficult to treat, and while many antibiotics are approved for children, drug allergies or intolerances can prohibit their use. Intravenous imipenem/cilastatin is among the preferred antibiotics for treatment of M. abscessus, however, its use may result in systemic toxicities including hepatic injury and gastrointestinal effects.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, we exposed apically well-differentiated human NECs cultured at the ALI to the related flaviviruses ZIKV, JEV, WNV, and Usutu virus (USUV). We selected these viruses due to the recent increasing evidences of potential threat to humans (Cadar et al., 2017; Simonin et al., 2018). We show that NECs are particularly susceptible to JEV and WNV infection and to other flaviviruses included in this study. Infection with each virus led to shedding of infectious virus particles through the apical and basolateral surfaces and triggered host mechanisms at the level of inflammatory and antiviral mediators. Given...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
In this study, we sought to further characterize ILC2s in the kidney, their location within this organ and determine their functional role in IRI using a loss-of-function approach. Here, we found that kidney ILC2s constitutively express IL-5 and are primarily located in close proximity to the renal vasculature, within the adventitia. Additionally, we demonstrate that a reduction, deficiency or depletion of ILC2s had minimal impact on the severity of IRI. Whilst activation of ILC2s and the associated amplification of local type 2 immunity has been previously shown to reduce the deleterious consequences of AKI, our results r...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Cystic Fibrosis | Marketing | Pharmaceuticals | Rheumatology